ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
Characteristics and treatment options of 272,152 geriatric patients with very high and high fracture risk.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fracture liaison services: successful implementation in Belgium using a regional healthcare quality improvement initiative.Archives of osteoporosis · 2026Article
- Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide for osteoporosis: a bicenter retrospective study and analysis of the French national pharmacovigilance database.Archives of osteoporosis · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our study of 272,152 geriatric patients assessed osteoporosis treatment requirement and eligibility. Over 75% qualified for therapy, with 54% at very high fracture risk, classifying for bone anabolic treatment. Despite contraindications in 8-20%, most were suitable for treatment. Especially in geriatric patients, early risk-assessment and timely intervention are essential. PURPOSE: The German osteoporosis guideline defines high and very high fracture-risk based on quantifiable evidence-based risk-factors, recommending bone anabolic treatment as first-line therapy for the latter. Given age as a major risk factor, we investigated the proportion of geriatric patients with very high fracture risk, their characteristics, and the percentage suitable for bone anabolic treatment considering contraindications.
methodsData from the Geriatrics in Bavaria-Database (GiB-DAT, Geriatrie in Bayern Datenbank) included 272,152 participants (mean age 82 ± 7 years) between 2013 and 2023. Risk-factors and contraindications were evaluated using ICD-10- (International Statistical Classification of Diseases) and ATC-codes (Anatomical Therapeutical Chemical Classification). We analyzed the proportion in the high-risk and very high-risk group, their characteristics, and the share with a contraindication for specific anti-osteoporotic treatments.
results> 75% of the patients qualified for specific anti-osteoporotic treatment, with the majority (54%) at very high-risk requiring bone anabolic treatment. Patients in the very high-risk group had the lowest mini mental status examination (MMSE) (23 ± 5 points) and activities of daily living (ADL) scores (45 ± 20 points). Contraindications for bone anabolic treatments were found in 20% of women and 8% of all very high-risk patients. Seventy percent of the total study population had no contraindication for any specific anti-osteoporotic medications.
conclusionThe majority of geriatric patients is at a very high-risk for osteoporotic fractures, characterized by cognitive impairment, ADL limitations, and increased vulnerability. While some patients had contraindications, most were eligible for anti-osteoporotic and particularly bone anabolic treatments. Timely risk-assessment and treatment initiation is crucial and barriers need to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.